Newsroom

Sorted by: Latest

-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

KW Stock Alert: Halper Sadeh LLC is Investigating Whether Kennedy-Wilson Holdings, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Kennedy-Wilson Holdings, Inc. (NYSE: KW) to a consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy-Wilson, and certain other senior executives of Kennedy-Wilson, together with Fairfax Financial Holdings Limited, for $10.90 per share in cash. Halper Sadeh encourages Kennedy-Wilson shareholders to click here to learn more about their rights and options or contact D...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 16.02.2026 MSEP.LN IE0009DRFET8 100,002.00 USD 2,708,226.61 27.082  ...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 16.02.2026 RDVY LN IE000K5F6EL4 825,002.00 USD 18,787,135.68 22.772  ...
-

Ameresco, Luminace and the Town of Coventry Announce the Completion of Coventry Landfill Solar Project

FRAMINGHAM, Mass. & COVENTRY, R.I.--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy infrastructure solutions provider, and Luminace, one of the largest decarbonization-as-a-service providers in North America, jointly announced the successful completion of the Coventry Landfill Solar project. This milestone marks a significant advancement in the Town of Coventry’s efforts to expand renewable energy generation and enhance long‑term environmental stewardship. The Town of Coventry’s...
-

Boyd More than Doubles Liquid Cooling Manufacturing Capacity in Mexico, Boosting Production for AI Infrastructure, Hyperscale and Colocation Data Centers

BOCA RATON, Fla.--(BUSINESS WIRE)--Boyd doubles its Juarez Thermal facility to scale liquid cooling system production for rapidly growing AI data center demand....
-

Butterfly Network to Participate at TD Cowen 46th Annual Health Care Conference on March 3, 2026

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that it will participate at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, EVP, Chief Financial Officer; and Megan Carlson, SVP, Accounting & Finance – Chief Acc...
-

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy. “We are excited to achieve this im...
-

Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology

GENEVA--(BUSINESS WIRE)--Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology...